⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584212 | 1.00 | — | — | |
| SCHEMBL100581 | 0.97 | — | — | |
| SCHEMBL101996 | 0.88 | — | — | |
| SCHEMBL8763991 | 0.72 | ALDH1A1 (0.39) | — | |
| SCHEMBL8763101 | 0.72 | — | — | |
| SCHEMBL8763092 | 0.72 | — | — | |
| SCHEMBL8763984 | 0.72 | ALDH1A1 (0.39) | — | |
| SCHEMBL8763215 | 0.69 | — | — | |
| SCHEMBL8462648 | 0.69 | — | — | |
| SCHEMBL1672492 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886814-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| WO-2014167530-A1 | CANNABINOID COMPOUNDS | BOWDEN MATTHEW JAMES (NZ) | 2014-10-16 | — | — | WO | claimed |
| US-6376493-B1 | SELECTIVE INHIBITION OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR; USEFUL IN TREATING OSTEOPOROSIS, TUMORS, AUTOIMMUNE DISEASES, RHEUMATIC DISEASES, AND ASTHMA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2002-04-23 | — | — | US | claimed |
| CN-117886814-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2014167530-A1 | CANNABINOID COMPOUNDS | BOWDEN MATTHEW JAMES (NZ) | 2014-10-16 | — | — | WO | disclosed |
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1641759-B1 | MALONAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-1653951-B1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| WO-1999065880-A1 | ARYL ALKANOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 1999-12-23 | — | — | WO | disclosed |
| US-5859008-A | Arylalkyl diazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-01-12 | — | — | US | disclosed |
| US-5747489-A | Arylalkyl-thiadiazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-05-05 | — | — | US | disclosed |
| EP-0763534-A1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GmbH (DE) | 1997-03-19 | — | — | EP | disclosed |
| EP-0738715-A2 | Arylalkyl-pyridazinones | MERCK PATENT GmbH (DE) | 1996-10-23 | — | — | EP | disclosed |
| EP-0723962-A1 | Arylalkyl-thiadiazinones | MERCK PATENT GmbH (DE) | 1996-07-31 | — | — | EP | disclosed |
| EP-0394440-B1 | PHENYLCARBOXYLIC ACID DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1994-05-11 | — | — | EP | disclosed |
| US-4999378-A | Antilipemic, anticholesterol, antidiabetic, treatment of atherosclerosis and obesity | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-03-12 | — | — | US | disclosed |
| EP-0394440-A1 | PHENYLCARBOXYLIC ACID DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |